comparemela.com

Latest Breaking News On - Michael kreuter - Page 1 : comparemela.com

Brainomix Showcases Growing Evidence for its Novel AI-Based Imaging Biomarkers in Lung Fibrosis

The company unveiled a series of new studies highlighting the prognostic value of its imaging biomarkers in patients with fibrotic lung diseaseThe studies reflect the company's expanding Life

United statesCity ofUnited kingdomSan diegoBaden wübergSue charlesAvalyn pharmaMichalis papadakisPrnewswire brainomixRoss stewartMichael kreuterPeter georgeJeff wyrtzenHeidelberg universityLung center mainzMarketing business development

Progressive Pulmonary Fibrosis: Treatment and Support

Numerous unresolved questions surround PPF treatment and support.

United kingdomZuid hollandMichael kreuterMarliess wijsenbeekElisabeth robertsonElisabeth bendstrupInternational congressDepartment of clinical medicineDepartment of respiratory diseasesErasmus university medical centre in rotterdamEuropean respiratory societyAarhus universityUniversity hospital in mainzLung centerClinical medicineRespiratory diseases

Diagnosing Progressive Pulmonary Fibrosis

Renowned medical professionals and experts congregated in Milan to explore the current and future prospects of diagnosing PPF.

University hospitalNew yorkUnited statesZuid hollandUnited kingdomMarliess wijsenbeekElisabeth robertsonMichael kreuterAnna podolanczukWeill cornell medical collegeEuropean respiratory societyLung center at university hospitalNew york cityLung centerInterstitial lung disease centreErasmus university medical centre

ERS 2023: Seeking a Healthy Environment for the Lungs

The hybrid meeting promises education, collaboration, and a focus on climate change for professionals in pulmonary and critical care medicine.

Katerina antoniouGerriet blumTorsten gerriet blumNajibm rahmanApostolos bossiosWinfried randerathMarisa bonsignoreChristian karagiannidisMona lichtblauOmar usmaniCarlos winckMarielle pijnenburgMichael kreuterHolly keirPrecision medicine in airway diseaseInternational congress

Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

/PRNewswire/ Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),.

United statesMichael kreuterTamera corteToby maherKevin flahertyCarl johan dalsgaardDepartment of internal medicinePrnewswire vicore pharma holdingDivision of pulmonary critical care medicineVicore pharma holdingUniversity of michiganProfessor toby maherKeck schoolSouthern californiaProfessors kevin flahertyCritical care medicine

vimarsana © 2020. All Rights Reserved.